Iron is a paradox in human biology — essential for life yet lethal in excess. A newly published review in Autophagy reframes how the body's own iron-recycling machinery, when dysregulated, may quietly drive damage to the heart, liver, lungs, and kidneys through a process called ferritinophagy — a finding with implications for some of medicine's most treatment-resistant organ injuries.
Ferritinophagy is a selective subtype of macroautophagy in which the cargo receptor NCOA4 binds ferritin complexes and shuttles them to lysosomes for degradation, releasing stored iron back into the cytosol. Under normal conditions, this maintains intracellular iron homeostasis during metabolic stress. However, when the process becomes excessive or uncontrolled, free iron accumulates, catalyzing Fenton reactions that generate reactive oxygen species. This oxidative cascade activates ferroptosis — an iron-dependent, non-apoptotic cell death pathway — while simultaneously triggering inflammatory signaling. The review systematically maps how this sequence unfolds in cardiac tissue, hepatocytes, pneumocytes, and renal tubular cells, identifying organ-specific vulnerabilities and molecular entry points including BECN1, ATG proteins, CARM1, and CIRBP across pathologies ranging from acute kidney injury to ARDS and COPD.
What makes this review analytically valuable is the convergence it identifies between two previously somewhat siloed fields — autophagy research and ferroptosis biology — with ferritinophagy serving as a mechanistic bridge. The iron-ferroptosis axis has gained considerable momentum since ferroptosis was formally characterized in 2012, but its upstream regulation via selective autophagy is underappreciated in clinical contexts. A key limitation of this work is that it is a narrative review, not a meta-analysis or original trial; many of the mechanistic insights are drawn from animal models and in vitro systems, with human translational evidence still sparse. Nevertheless, the identification of ferritinophagy as a druggable node — potentially targetable by NCOA4 modulators or iron chelation strategies — positions this as an incremental but directionally significant contribution that could inform future therapeutic development for acute and chronic organ failure.